Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program ...

The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Vabysmo or Susvimo to help minimize barriers to access and ...

With more than 2,000 industry professionals, Veeva Commercial Summit is the largest commercial and medical event in North America. More than 40 sponsoring partners include Accenture, Conexus, ...

In patients with diabetic macular edema, small gauge pars plana vitrectomy should be considered as a first-line treatment, ...

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

MOGAD is a rare autoimmune disease of the central nervous system characterized by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitating Data will be ...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association ...